Dementia and Alzheimer Disease

The FDA has granted 510(k) clearance to VoxNeuro's Cognitive Function Neuroimaging software, an EEG/ERP-based tool designed to give clinicians an objective, adjunctive measure of cognitive function.

Neurologist Takaomi Saido, PhD, discusses decades of research into the neprilysin-donanemab and amyloid-beta–tau axes in Alzheimer disease, highlighting potential mechanisms underlying the transition from amyloid to tau pathology and opportunities to develop earlier, more targeted disease-modifying therapies.

Six FDA PDUFA decisions this fall could reshape care in Alzheimer disease, DMD, Sanfilippo syndrome, Alexander disease, and SMA, here's what clinicians need to know about the data behind each.

Catch up on any of the neurology headlines you may have missed in July 2026, compiled into 1 place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 31, 2026.

Experts discuss how plasma biomarkers may enable earlier detection of Alzheimer disease pathology, including in cognitively unimpaired individuals and those with subjective cognitive decline, while offering a more accessible alternative to CSF and PET-based assessment. [WATCH TIME: 8 Minutes]

ProMIS Neurosciences reported no cases of ARIA-E in a six-month blinded interim analysis of PMN310, an oligomer-selective antibody in the phase 1b PRECISE-AD trial for Alzheimer disease, alongside early biomarker signals consistent with target engagement.

Phase 1b data published in Nature Medicine and presented at AAIC 2026 showed target engagement and reductions in select cerebrospinal fluid biomarkers of neuronal and synaptic injury with the investigational anti-PD-L1 antibody.

Extended follow-up and new AAIC 2026 data show that tazbentetol, a first-in-class oral synaptic regenerative therapy, produced rapid and durable improvement in cognition and EEG biomarkers in patients with mild-to-moderate Alzheimer disease.

Here's some of what is coming soon to NeurologyLive® this week.

A 12-week, placebo-controlled phase 2 trial found that an oral THC/CBD combination significantly reduced agitation in hospice-eligible patients with Alzheimer disease and other dementias, meeting its primary and key secondary endpoints.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 24, 2026.

Stephen Williams, PhD, chief scientific officer of Alamar Biosciences, discusses the potential of eMTBR-tau measurement, multiplex biomarker testing, and AI-driven approaches to improve the characterization of Alzheimer disease and its coexisting pathologies.

Kristen Harris, MD, Medical Director of the Extended Recovery Unit at Hackensack Meridian JFK Johnson Rehabilitation Institute, discussed new findings on functional recovery and community discharge rates in acquired brain injury patients undergoing skilled nursing facility rehabilitation.

Ahead of World Brain Day, NeurologyLive explores 5 emerging strategies for preventing neurologic disease, from modifiable dementia risk factors to GLP-1 drugs, sleep science, the gut brain axis, and wearable technology.

From concussion recognition to blood-based biomarkers and the long-term effects of repetitive heading, neurologists discuss how emerging research is changing the understanding of brain injury in the world's most popular sport.

From concussion recognition to blood-based biomarkers and the long-term effects of repetitive heading, neurologists discuss how emerging research is changing the understanding of brain injury in the world's most popular sport.

Laura Nisenbaum, PhD, Interim Chief Science Officer at the Alzheimer's Drug Discovery Foundation, shares her perspective on the FDA's approval of a subcutaneous starting dose for lecanemab and what it means for access, clinical practice, and the future of Alzheimer disease treatment.

Understanding how amyloid pathology develops years before symptoms emerge is essential to appreciating the growing role of blood-based biomarkers in earlier Alzheimer disease detection.

The $100 million PROTECT-Cog trial will test whether adding a GLP-1 drug to the proven U.S. POINTER lifestyle intervention further cuts dementia risk in at-risk older adults.

PrevenTRON, a study of trontinemab, will enroll 1600 cognitively unimpaired participants identified by elevated plasma p-tau217, using time to clinical progression as the primary endpoint.

SAR448851 showed favorable safety, high CNS penetration, and up to 50% reductions in CSF soluble TREM2 in phase 1, supporting the design of TREMHANCE, a phase 2 trial now in final planning with p-tau217 as its primary endpoint.

Neurology News Network for the week ending July 18th, 2026. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 17, 2026.